Loading clinical trials...
Loading clinical trials...
Efficacy and Mechanism of Transcutaneous Vagus Nerve Stimulation in the Treatment of Generalized Anxiety Disorder
This is a randomized, double-blind, parallel-controlled study of patients with generalized anxiety disorder, who will be randomly assigned to either drug-combined transcutaneous vagus nerve stimulation (tVNS) group or drug-combined sham-stimulation group for a period of 4 weeks of treatment.Scale assessments will be performed at baseline, week 1, week 2, week 3, and week 4 of treatment, and brain function monitoring as well as laboratory tests will be performed at baseline and at the end of treatment, respectively.The aim of this study is to investigate the efficacy of medication combined with tVNS and the possible mechanisms of tVNS in the treatment of anxiety.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
The First Affiliated Hospital of Air Force Military Medical University
Xi'an, Shaanxi, China
Xi'an No.3 Hospital
Xi'an, Shaanxi, China
Start Date
December 5, 2023
Primary Completion Date
August 30, 2025
Completion Date
September 30, 2025
Last Updated
December 20, 2023
82
ESTIMATED participants
medication-combined transcutaneous vagus nerve stimulation
DEVICE
medication-combined sham stimulation
DEVICE
Lead Sponsor
Xijing Hospital
NCT07429578
NCT06661460
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions